The change of disease burden of CRD in different region, 1990-2021. حسب Yanrong Yin (14292683)

Average proportion of first choice female applicants stratified by specialty category. حسب Lucy Hui (17538542)

Gender differences in first choice match outcomes. حسب Lucy Hui (17538542)

Total number of applications to each discipline grouped by (a) clinical disciplines, (b) diagnostic disciplines, and (c) surgical disciplines. حسب Lucy Hui (17538542)

Number of applicants matched to each discipline grouped by (a) clinical disciplines, (b) diagnostic disciplines, and (c) surgical disciplines. حسب Lucy Hui (17538542)

Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

"…<p>In the recurrence group, BCVA (logMAR ± standard deviation) showed no significant change from baselines (0.37 ± 0.20) to 0.35 ± 0.23, 0.35 ± 0.18, 0.31 ± 0.23, 0.34 ± 0.26, 0.28 ± 0.30, and 0.24 ± 0.23 at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal–Wallis test, P = 0.45). …"

Data Sheet 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx حسب David Qixiang Chen (8198265)

"…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …"

Data Sheet 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx حسب David Qixiang Chen (8198265)

"…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …"

Data Sheet 3_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx حسب David Qixiang Chen (8198265)

"…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …"

Patient characteristics before and after propensity score matching. حسب Anna D. Ware (19688153)

الموضوعات:

An <i>In Situ</i> TEM Study of the Diffusivity of Gold Atoms in Nanocomposite Thin Films by Zirconia Co-Deposition: Implication for Neuromorphic Devices حسب Alberto Casu (1285227)

الموضوعات:

An <i>In Situ</i> TEM Study of the Diffusivity of Gold Atoms in Nanocomposite Thin Films by Zirconia Co-Deposition: Implication for Neuromorphic Devices حسب Alberto Casu (1285227)

الموضوعات:

Unadjusted and adjusted odds ratios (95% confidence interval) for associations between patients who were prescribed aspirin at baseline and the occurrence of post-COVID-19 acute th... حسب Anna D. Ware (19688153)

الموضوعات:

Forest plot displaying the association (odds ratio [95% CI]) between patients who were prescribed aspirin at baseline and the occurrence of post-COVID-19 acute thromboembolic disor... حسب Anna D. Ware (19688153)

الموضوعات:

Patient flowchart. حسب Anna D. Ware (19688153)

الموضوعات:

An <i>In Situ</i> TEM Study of the Diffusivity of Gold Atoms in Nanocomposite Thin Films by Zirconia Co-Deposition: Implication for Neuromorphic Devices حسب Alberto Casu (1285227)

الموضوعات:

An <i>In Situ</i> TEM Study of the Diffusivity of Gold Atoms in Nanocomposite Thin Films by Zirconia Co-Deposition: Implication for Neuromorphic Devices حسب Alberto Casu (1285227)

الموضوعات:

An <i>In Situ</i> TEM Study of the Diffusivity of Gold Atoms in Nanocomposite Thin Films by Zirconia Co-Deposition: Implication for Neuromorphic Devices حسب Alberto Casu (1285227)

الموضوعات:

An <i>In Situ</i> TEM Study of the Diffusivity of Gold Atoms in Nanocomposite Thin Films by Zirconia Co-Deposition: Implication for Neuromorphic Devices حسب Alberto Casu (1285227)

الموضوعات:

Frequency of post-COVID-19 acute thromboembolic disorders among aspirin users vs. non-users within 12 months following index date. حسب Anna D. Ware (19688153)

الموضوعات: